[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1112116T1 - Μεθοδος θεραπειας ασθενων με ηπατιτιδα c - Google Patents

Μεθοδος θεραπειας ασθενων με ηπατιτιδα c

Info

Publication number
CY1112116T1
CY1112116T1 CY20111101045T CY111101045T CY1112116T1 CY 1112116 T1 CY1112116 T1 CY 1112116T1 CY 20111101045 T CY20111101045 T CY 20111101045T CY 111101045 T CY111101045 T CY 111101045T CY 1112116 T1 CY1112116 T1 CY 1112116T1
Authority
CY
Cyprus
Prior art keywords
patients
treatment
relapsed
hepatitis
infection
Prior art date
Application number
CY20111101045T
Other languages
English (en)
Inventor
Janice K Albrecht
Clifford A Brass
Robert Orville Ii Ralston
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112116(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1112116T1 publication Critical patent/CY1112116T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Η εφαρμογή αυτή αποκαλύπτει νέα μέθοδο αναγνώρισης ασθενών μεταξύ πρωτοθεραπευόμενων ασθενών που πάσχουν από μόλυνση HCV οι οποίοι είναι επιδεκτικοί σε θεραπευτική αγωγή με αναστολέα πρωτεάσης. Η αίτηση επίσης αποκαλύπτει μέθοδο θεραπευτικής αγωγής πρωτοθεραπευόμενων, μη αποκρινόμενων και υποτροπιαζόντων ασθενών που πάσχουν από μόλυνση Ηπατίτιδας HCV.
CY20111101045T 2007-09-14 2011-11-01 Μεθοδος θεραπειας ασθενων με ηπατιτιδα c CY1112116T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99375307P 2007-09-14 2007-09-14
US99876207P 2007-10-12 2007-10-12
US149407P 2007-10-30 2007-10-30
EP08831728A EP2061513B1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients

Publications (1)

Publication Number Publication Date
CY1112116T1 true CY1112116T1 (el) 2015-11-04

Family

ID=40262964

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101045T CY1112116T1 (el) 2007-09-14 2011-11-01 Μεθοδος θεραπειας ασθενων με ηπατιτιδα c

Country Status (18)

Country Link
US (1) US20100226885A1 (el)
EP (2) EP2489369A1 (el)
JP (1) JP2010539165A (el)
CN (1) CN101883590A (el)
AT (1) ATE519503T1 (el)
AU (1) AU2008301981A1 (el)
CA (1) CA2699280A1 (el)
CY (1) CY1112116T1 (el)
DK (1) DK2061513T3 (el)
ES (1) ES2369321T3 (el)
HK (1) HK1129315A1 (el)
HR (1) HRP20110637T1 (el)
MX (1) MX2010002909A (el)
NZ (1) NZ583825A (el)
PL (1) PL2061513T3 (el)
PT (1) PT2061513E (el)
SI (1) SI2061513T1 (el)
WO (1) WO2009038663A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2704570A4 (en) * 2011-05-04 2015-02-18 Merck Sharp & Dohme ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
ES2659216T5 (es) 2011-09-16 2021-06-09 Gilead Pharmasset Llc Métodos para el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
PT107925A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2012332827A1 (en) 2011-10-31 2014-05-15 Gilead Pharmasset Llc Methods and compositions for treating hepatitis C virus
BR112014012739A8 (pt) * 2011-11-29 2017-06-20 Gilead Pharmasset Llc composições e métodos para o tratamento do vírus da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2809334A4 (en) 2012-02-01 2015-06-24 Abbvie Inc ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN
CN105748499B (zh) 2013-01-31 2018-12-28 吉利德制药有限责任公司 两个抗病毒化合物的联用制剂
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
PE20001548A1 (es) * 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
KR100939155B1 (ko) * 2000-07-21 2010-01-28 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN101076516A (zh) * 2004-02-27 2007-11-21 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物
WO2006016930A2 (en) * 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
EP1981524A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AU2009256623A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen

Also Published As

Publication number Publication date
WO2009038663A1 (en) 2009-03-26
DK2061513T3 (da) 2011-11-21
CA2699280A1 (en) 2009-03-26
PT2061513E (pt) 2011-10-17
MX2010002909A (es) 2010-03-30
ATE519503T1 (de) 2011-08-15
HK1129315A1 (en) 2009-11-27
ES2369321T3 (es) 2011-11-29
NZ583825A (en) 2012-06-29
CN101883590A (zh) 2010-11-10
US20100226885A1 (en) 2010-09-09
EP2061513B1 (en) 2011-08-10
PL2061513T3 (pl) 2011-12-30
EP2489369A1 (en) 2012-08-22
SI2061513T1 (sl) 2011-11-30
AU2008301981A1 (en) 2009-03-26
JP2010539165A (ja) 2010-12-16
HRP20110637T1 (hr) 2011-10-31
EP2061513A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
CY1112116T1 (el) Μεθοδος θεραπειας ασθενων με ηπατιτιδα c
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CY1112259T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DK2219642T3 (da) Silibininbestandel til behandling af hepatitis
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
GEP20084545B (en) Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
ATE443769T1 (de) Impfstoff zur prävention und behandlung von einer hiv-infektion
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
HK1096320A1 (en) Apheresis device
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE548044T1 (de) Kombinationstherapie zur behandlung von hiv- infektionen
NO20072285L (no) S-mirtazapin for behandling av hetetokter
EP2224943A4 (en) USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
WO2006034001A3 (en) Methods of treating hiv infection
DE602008002832D1 (de) Keramische zahnspange mit verbesserten löseeigenschaften
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
UA90477C2 (ru) Способ лечения гепатита с (варианты)
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
FI20085282A0 (fi) Biotekninen prosessi rautaa sisältävien mineraalien, konsentraattien, steriilien prosessivesien ja yhdisteiden käsittelemiseksi
UA2826U (uk) Спосіб лікування розсіяного склерозу